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Investigation of mouse macrophage-like RAW264.7 cells showed that the immunostimulatory 
activity of CpG DNA is increased by formation of polypod-like structured DNA (polypodna), 
an assembly consisting of three or more oligodeoxynucleotides. To apply CpG polypodna to 
immunotherapy, its activity was examined in murine dendritic DC2.4 cells, splenic 
macrophages, and bone marrow-derived dendritic cells (BMDCs). In all cell types, increasing 
the pod number increased the cellular uptake of DNA and cytokine release. No significant 
release of cytokines was observed in macrophages lacking Toll-like receptor 9. Similar results 
were obtained after intradermal injection of polypodna. The polypodna preparations produced 
significantly higher amounts of interferon  in human peripheral blood mononuclear cells 
(PBMCs) compared with single-stranded DNA. The conditioned medium of 
hexapodna-treated human PBMCs effectively inhibited activity of a hepatitis C virus 
subgenomic replicon reporter system. These results indicate that polypodna preparations are 
useful as an immunostimulator. 
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Stimulation of innate immune cells leads to secretion of proinflammatory cytokines, which, in 
turn, causes inflammation. Such inflammation is likely essential for the induction of efficient 
immune responses to a variety of pathogens.
1
 Ligands for Toll-like receptors (TLRs) have
therapeutic potential, because TLR ligation initiates a signaling pathway that activates nuclear 
factor B, which is a master transcription factor controlling the expression of 
proinflammatory cytokines. 
One of the most-studied TLR ligands is DNA containing unmethylated 
cytosine-phosphate-guanine dinucleotides (CpG motifs), the ligand for TLR9.
2,3
 This specific
DNA is abundant in viral, bacterial and mitochondrial DNA, and it is categorized as a 
pathogen- or damage-associated molecular pattern.
4
 TLR9 ligation induces the release of
cytokines such as tumor necrosis factor (TNF)-, interleukin (IL)-12 and interferon 
(IFN)-.5-8 Although natural phosphodiester CpG DNA is a ligand for TLR9, its susceptibility
to enzymatic degradation limits its therapeutic applications. Therefore, 
phosphorothioate-stabilized CpG DNA has been used to induce cytokine production.
9,10
 This
stabilized DNA, however, is associated with adverse reactions, such as renal damage.
11
Therefore, other approaches for increasing the activity of CpG DNA are required to enhance 
its therapeutic potency. 
Recent advances in DNA nanotechnology have resulted in the development of 
uniquely structured DNA assemblies. CpG DNA has been linked with or incorporated into 






 and DNA origami.
16
 We have recently developed a series of polypod-like
structured DNAs, or polypodna, which is a DNA assembly consisting of three or more 
oligodeoxynucleotides (ODNs), and found that the immunostimulatory activity of CpG DNA 
is a function of the structural characteristics of the polypodna. For example, both pod number 
4 
and size are important parameters that determine the cellular uptake of polypodna 
preparations in mouse macrophage-like RAW264.7 cells and the following cytokine 
production.
17
Despite these advances, additional studies of CpG DNA-containing polypodna in 
cells other than RAW264.7 are required, since the cellular response to CpG DNA is highly 
cell type- and species-specific.
18, 19
 Human macrophages do not express TLR9,
20
 and the
major human cells responding to CpG DNA are considered to be plasmacytoid dendritic 
cells.
21
 In addition, we have demonstrated that primary macrophages respond differently to
CpG DNA than RAW264.7 cells.
19 
Based on these considerations, this study was designed to examine the 
immunostimulatory activity of polypodna in murine immune cells that play important roles in 
the response to CpG DNA. We also examined the immunostimulatory activity of polypodna in 
vivo after intradermal injection into mice. Finally, human peripheral blood mononuclear cells 
(PBMCs) were also used to investigate whether polypodna preparations effectively activate 




Roswell Park Memorial Institute (RPMI) medium and Dulbecco’s modified Eagle’s medium 
(DMEM) powder were obtained from Nissui Pharmaceutical, Co., Ltd. (Tokyo, Japan). 
DMEM (liquid) was purchased from Life Technologies (Carlsbad, CA) and used only for 
LucNeo#2 cells. Opti-modified Eagle’s medium (Opti-MEM) and Iscove’s modified 
Dulbecco’s medium (IMDM) and MEM non-essential amino acids (NEAA) were purchased 
from Life Technologies. Fetal bovine serum (FBS) was obtained from Biowest (Nuaille, 
France), monothioglycerol and cytochalasin B were obtained from Wako Pure Chemical 
(Osaka, Japan), G418 was purchased from Nacalai Tesque (Kyoto, Japan), and chloroquine 
diphosphate salt, dansylcadaverine and lipopolysaccharide (LPS; L3014) were purchased 
from Sigma-Aldrich (St. Louis, MO). 
Animals 
Male C57BL/6 mice were purchased from Japan SLC, Inc (Shizuoka, Japan). TLR9 knockout 
(TLR9
-/-
) mice with a C57BL/6 genetic background were purchased from Oriental Yeast
Company (Tokyo, Japan). All animal experiments were conducted in accordance with the 
principles and procedures outlined in the National Institutes of Health Guide for the Care and 
Use of Laboratory Animals. The protocols for animal experiments were approved by the 
Animal Experimentation Committee of the Graduate School of Pharmaceutical Sciences, 
Kyoto University. 
Cell culture 
The murine macrophage-like cell line RAW264.7 was cultured in RPMI medium 
supplemented with 10% heat-inactivated FBS, 0.2% sodium bicarbonate, 100 IU/mL 
6 
penicillin, 100 μg/mL streptomycin and 2 mM L-glutamine. The murine dendritic cell line 
DC2.4 (kindly provided by Dr. K. L. Rock, University of Massachusetts Medical School, 
Worcester, MA) was cultured in RPMI medium supplemented with 10% heat-inactivated FBS, 
0.2% sodium bicarbonate, 100 IU/mL penicillin, 100 μg/mL streptomycin, 2 mM L-glutamine, 
0.5 mM monothioglycerol and 0.1 mM NEAA. These cells were replated on 24-well, 48-well 




 cells/well or 5×10
4
cells/well, respectively, and cultured for 24 h prior to use. LucNeo#2, a Huh-7 cell harboring 
self-replicating subgenomic hepatitis C virus (HCV) RNA replicons with a luciferase 
reporter,
22
 was kindly provided by Drs. Hijikata and Shimotohno of Institute for Virus
Research, Kyoto University, Japan. LucNeo#2 cells were cultured in DMEM supplemented 
with 10% FBS, 2 mM L-glutamine and 0.1 mM NEAA in the presence of 500 μg/mL G418. 
Preparation of mouse bone marrow-derived dendritic cells 
Bone marrow-derived dendritic cells (BMDCs) were generated from 8- to 10-week old male 
C57BL/6 mice as previously reported.
23
 Briefly, bone marrow cells were isolated by flushing
femurs and tibiae with RPMI using a 26-gauge needle. After filtration through a 40 μm cell 
strainer (BD Falcon, Franklin Lakes, NJ), bone marrow cells were resuspended in 0.86% 
ammonium chloride for 5 min to lyse the red blood cells. Then, the remaining cells were 
cultured for 8 days at a density of 5×10
6
 cells/mL in RPMI supplemented with 10%
heat-inactivated FBS, 0.2% sodium bicarbonate, 100 IU/mL penicillin, 100 μg/mL 
streptomycin, 2 mM L-glutamine, 0.5 mM monothioglycerol, and 100 ng/mL mouse 
recombinant Flt-3 ligand (Peprotech, Rocky Hill, NJ). Cells were grown in humidified air 
containing 5% CO2 at 37C. On day 7 of culture, non-adherent cells were harvested and used 
as BMDCs. Cells were replated on 96-well culture plates at a density of 3×10
5
 cells/well for
the cytokine release experiment. 
7 
 
Isolation of mouse splenic macrophages 
Spleens were removed aseptically from 8- to 10-week old male C57BL/6 mice, divided with a 
spatula and filtered through a 40 μm cell strainer (BD Falcon) to obtain single-cell 
suspensions. Red blood cells were lysed by exposure to 0.86% ammonium chloride for 5 min. 
After washing three times with phosphate buffered saline (PBS), splenocytes were suspended 
in RPMI medium supplemented with 10% FBS, penicillin G (100 U/mL), streptomycin (100 
mg/mL), and 0.5 mM monothioglycerol, and plated in 10-cm culture dishes. After a 3 h 
incubation in humidified air containing 5% CO2 at 37C, adherent macrophages were washed 
twice with RPMI-1640 medium to remove non-adherent cells and replated at a density of 
4×10
5
 cells/well on 48-well or 96-well culture plates. 
 
Isolation of human peripheral blood mononuclear cells 
All experiments using human cells were approved by the Institutional Review Board at the 
Graduate School of Medicine, Kyoto University, and following the tenets of the Declaration 
of Helsinki. Human PBMCs were obtained from healthy donors after obtaining their written 
informed consent. In brief, PBMCs were isolated from peripheral blood using Ficoll-Plaque 
PLUS (GE Healthcare Piscataway, NJ) density gradient centrifugation according to the 
manufacturer’s protocol. PBMCs collected were replated on 48-well culture plates at a density 
of 6×10
5
 cells/well in Opti-MEM. There were considerable individual differences in the 
response of cells to CpG DNA, and only highly responsive cells were used for experiments. 
 
Oligodeoxynucleotides 
Oligodeoxynucleotides (ODNs) with a length of 36-mer were purchased from Integrated 
DNA Technologies, Inc (Coralville, IA). The sequences of the ODNs are listed in Tables 1 
8 
and 2. Each ODN was given a name, such as mTri-1, hTri-1 and so on, with ‘m’ for mouse 
and ‘h’ for human, Tri, Tetra, Pen, Hex for tripodna, tetrapodna, pentapodna and hexapodna, 
respectively, and the ODN number. The ODNs for CpG polypodna for mouse cells were 
identical to those used in a previous study.
17
 For cellular uptake studies, mTri-2 labeled with 
Alexa Fluor-488 at the 5′ end was purchased from Japan BioService Co., Ltd. (Saitama, 
Japan).  
 
Preparation of polypodna 
Polypodna samples were prepared by mixing equimolar amounts of their components as 
previously reported.
17
 In brief, ODNs dissolved in an annealing buffer (10 mM Tris-HCl, pH 
8.0, 1 mM ethylenediaminetatraacetic acid, and 150 mM sodium chloride) were mixed at a 
final concentration of 0.1 mM for each ODN. The mixtures of ODNs were annealed by 
heating them to 95°C and gently cooling to 4°C using a thermal cycler. Then, the 
concentrations of DNA samples were normalized. For cellular uptake studies, Alexa Fluor 
488-labeled mTri-2 was used instead of mTri-2. The products of polypodna preparations were 
analyzed by 6 % polyacrylamide gel electrophoresis (PAGE) at room temperature at 200 V for 
20 min and stained with ethidium bromide for visualization. 
 
Cytokine release 
Cells were incubated with single-stranded (ss) DNA (mTri-2 for mouse cells or hTri-2 for 
human PBMCs) or polypodna at the indicated concentrations for 24 h. Then, culture 
supernatants were collected for enzyme-linked immunosorbent assay (ELISA) and kept at 
-80°C until use. Appropriate cytokines that are highly released from each type of cell were 
selected as indicators of cellular stimulation. The levels of mouse IL-6, the p40 subunit of 
IL-12 (IL-12p40) and tumor necrosis factor (TNF)- were determined using OptEIATM sets 
9 
(Pharmingen, San Diego, CA). The levels of human IFN- were determined using the 
IFN--ELISA module set (Bender Med Systems, Vienna, Austria).    
 
Cellular uptake of polypodna 
DC2.4 cells (5104 cells/well) or splenic macrophages (4105 cells/well) on 96-well culture 
plates were incubated with 2 μg/mL Alexa Fluor 488-labeled DNA samples for 8 or 4 h, 
respectively, at 37°C or 4C. Then, cells were washed twice with 200 L PBS and harvested. 
Finally, the fluorescence intensity of the cells was determined by flow cytometry (FACS 
Calibur, BD Biosciences, Franklin Lakes, NJ) using CellQuest software (version 3.1, BD 
Biosciences), and the mean fluorescent intensity (MFI) was calculated as an indicator of 
cellular uptake. To compare the cellular uptake of ssDNA and polypodna preparations, a 
normalized MFI was calculated by multiplying the MFI obtained with the fraction of Alexa 
Fluor 488-labeled ODN in samples, because the amount of Alexa Fluor 488-labeled ODN in 
the DNA samples was not identical. 
 
Effect of inhibitors on cytokine release and cellular uptake in DC2.4 cells 
Chloroquine (an inhibitor of endosomal fusion and acidification), dansylcadaverine (an 
inhibitor of clathrin-mediated endocytosis), and cytochalasin B (an inhibitor of phagocytosis) 
were used to examine the mechanisms involved in the cellular uptake of polypodna 
preparations. Cells were preincubated for 30 min with 6.25 M chloroquine, 25 M 
dansylcadaverine, or 5 M cytochalasin B, then incubated with CpG hexapodna or LPS in the 
presence of each inhibitor for 24 h. LPS, a ligand for Toll-like receptor 4, was used to confirm 
whether the DC2.4 cells treated with these inhibitors have the ability to release IL-6. IL-6 
release and cellular uptake were examined as described above.   
10 
 
IL-12p40 production in mice 
Under anesthesia with isoflurane, mice were injected with saline with or without ssDNA, 
CpG tripodna or CpG hexapodna into the dorsal skin at a dose of 100 μg DNA/mouse. At 1, 3, 
6, and 9 h after injection, the blood was collected from the tail vein of mice and serum was 
collected by centrifugation and stored at -20°C until analysis. The levels of IL-12p40 in the 
serum were determined by ELISA as described above. 
 
Inhibition of HCV replication in an HCV subgenomic replicon system 
LucNeo#2 cells were used to examine the inhibition of HCV replication by conditioned media 
of polypodna-treated human PBMCs, because the luciferase activity of the cells can be used 
as an indicator of HCV replication. Human PBMCs were incubated with ssDNA or CpG 
hexapodna at a concentration of 2 μg DNA/mL as described above. Then, the supernatant was 
collected as the conditioned medium. LucNeo#2 cells were replated at a concentration of 
2104 cells/well on 48-well culture plates and cultured for 24 h in DMEM supplemented with 
10% FBS, 100 IU/mL penicillin, 100 μg/mL streptomycin, and 2 mM L-glutamine. Then, the 
conditioned medium of PBMCs was diluted 20-fold with DMEM and added to LucNeo#2 
cells, and the cells were harvested after a 24-h culture and lysed. HCV replication was 
estimated by measuring the luciferase activity of the cell lysates in a luminometer Lumat LB 
9507 (Berthold Technologies, Bad Wildbad, Germany). 
 
Statistical analysis 
Differences were statistically evaluated by one-way analysis of variance followed by a Tukey- 
Kramer multiple comparisons test for multiple comparison or by Student’s t-test for 





Cytokine release and uptake after addition of polypodna to mouse dendritic DC2.4 cells 
Figure 1 shows the sequence and planar representation of CpG polypodna consisting of three, 
four, five, or six ODNs for mouse cells. Each ODN was identified with different colors. 
Figure 2A shows the IL-6 concentrations in the culture media of DC2.4 cells after addition of 
ssDNA or polypodna preparations containing CpG motifs. All polypodna preparations 
examined, i.e., tri-, tetra-, penta- and hexapodna, induced higher levels of IL-6 than ssDNA, 
although the same amount of DNA was added to the cells. The amount was almost 
proportional to the amount of DNA added and was the highest after addition of hexapodna, 
followed by pentapodna, tetrapodna, and tripodna, in this order. Similar results were obtained 
when the levels of TNF- in the culture media were measured (data not shown). Figure 2B 
shows the normalized mean fluorescent intensity (MFI) values of DC2.4 cells after 8 
h-incubation with Alexa Fluor 488-labeled ssDNA or polypodna preparations at 37°C. The 
higher the pod number, the greater the MFI values of the cells. The MFI values of cells 
incubated with DNA samples at 4°C were much lower than those at 37°C (data not shown). 
 
Effect of inhibitors on IL-6 release and cellular uptake in DC2.4 cells 
Figure 2C shows the IL-6 concentrations in the culture media of DC2.4 cells after addition of 
CpG hexapodna in the presence or absence of uptake inhibitors. All the inhibitors used 
significantly attenuated IL-6 release from the cells. Almost no IL-6 was released when 
chloroquine or cytochalasin B was added to the cells. When cells were treated with LPS, 
significant amounts of IL-6 were released, indicating that the cellular functions to release the 
cytokine were not impaired by the treatment. Figure 2D shows the MFI values of cells treated 
with each inhibitor followed by with Alexa Fluor 488-labeled hexapodna. Chloroquine had 
relatively little effect on the cellular uptake of Alexa Fluor 488-labeled hexapodna, whereas 
13 
dansylcadaverine or cytochalasin B significantly reduced the uptake. 
 
IL-12 release from mouse splenic macrophages 
To investigate the responsiveness of primary immune cells to polypodna preparations, mouse 
splenic macrophages were used. Because splenic macrophages release higher amounts of 
IL-12 than IL-6,
5
 IL-12p40 was measured as an indicator of the activation of splenic 
macrophages. Figure 3A shows IL-12p40 concentrations in the culture media of splenic 
macrophages of C57/BL6 mice. The concentrations of IL-12p40 rose as the pod number 
increased. To confirm the importance of CpG motifs on cytokine release from splenic 
macrophages, DNA samples containing GpC sequences instead of CpG were added to splenic 
macrophages (Figure 3B). No significant amounts of IL-12p40 were released when DNA 
containing GpC sequences were added. DNA sensors other than TLR9 have also been 
reported to be involved in the DNA-mediated production of cytokines from immune cells.
24
 
To determine if alternative sensors were involved in the responses, we examined cytokine 
release in splenic macrophages isolated from TLR9
-/-
 mice. As shown in Figure 3C, no 
significant release of IL-12p40 was observed from splenic macrophages of TLR9
-/-
 mice 
irrespective of the structure of CpG DNA.  
 
Uptake of polypodna in mouse splenic macrophages 
The differences in the release of IL-12p40 from splenic macrophages between wild-type and 
TLR9
-/-
 mice or between CpG and GpC samples might be due to the differences in the cellular 
uptake of DNA samples. Therefore, the uptake of Alexa Fluor 488-labeled hexapodna by 
splenic macrophages was examined (Figure 3D). There was no significant difference in the 
uptake of Alexa Fluor 488-labeled CpG hexapodna between wild-type and TLR9
-/-
 
macrophages. In addition, the uptake of Alexa Fluor 488-labeled GpC hexapodna by 
14 
wild-type macrophages was comparable with that of Alexa Fluor 488-labeled CpG 
hexapodna. 
 
IL-6 release from mouse BMDCs 
Figure 4 shows the IL-6 concentrations in the culture media of BMDCs of C57/BL6 mice 
after addition of ssDNA or polypodna preparations. BMDCs released large amounts of IL-6 
depending on the pod number. Again, no detectable IL-6 was released from BMDCs of 
TLR9
-/-
 mice (data not shown). 
 
IL-12p40 production by polypodna after intradermal injection in mice 
ssDNA, CpG tripodna, or CpG hexapodna was injected into mice by intradermal injection to 
examine IL-12p40 production by these preparations in vivo. Figure 5 shows the time course 
of the serum IL-12p40 levels of mice after injection of saline (vehicle) or DNA samples. No 
significant increase in the IL-12p40 level was observed in mice receiving saline or ssDNA. In 
contrast, the level significantly increased in mice receiving CpG tripodna or CpG hexapodna. 
 
IFN- release from human PBMCs 
Because the optimal CpG motif for human TLR9 is reportedly GTCGTT, which is not 
identical to the optimal murine sequence of GACGTT,
25
 polypodna preparations containing 
human CpG motifs were designed (Table 2). Figure 6A shows the PAGE analysis of ssDNA, 
tripodna, tetrapodna, pentapodna, and hexapodna. Every sample migrated as a single band on 
PAGE, indicating efficient formation of each polypodna preparation. Human PBMCs were 
incubated with ssDNA or polypodna preparations, and the release of IFN- was measured. 
Figure 6B shows the IFN- level in culture media of human PBMCs after addition of ssDNA 
or polypodna preparations. Compared with ssDNA, all polypodna preparations, except 
15 
tripodna, induced significantly higher amounts of IFN-, although there were no significant 
differences among the polypodna preparations.  
 
Inhibition of HCV replication by the conditioned media of PBMCs 
An HCV subgenomic replicon system was used to examine whether polypodna-induced 
cytokine production is effective in inhibiting HCV replication in Huh-7 human hepatoma cells. 
Figure 6C shows the luciferase activity of LucNeo#2 cells after incubation with or without 
addition of the conditioned medium of ssDNA- or hexapodna-treated PBMCs. The 
conditioned medium of the hexapodna-treated PBMCs reduced luciferase activity more 
effectively than that of the ssDNA-treated PBMCs. 




There are many strategies to increase the immunostimulatory activity of CpG DNA, including 
the use of nuclease-resistant DNA analogues.
9,10
 We have reported that building up CpG DNA 
into branched DNA assemblies, such as polypodna and dendrimer-like DNA, is a novel and 
effective approach to increasing the immunostimulatory activity of CpG DNA.
12, 14, 17, 26
 
Using mouse macrophage-like RAW264.7 cells, we reported that highly branched DNA 
assemblies are more effective than conventional single-stranded CpG DNA in inducing 
cytokine production. We also demonstrated that tetrapodna preparations are more effective 
than ssDNA in inducing IL12p40 in mice after injection into the footpad.
26
 The present study 
has extended this finding by showing that other immune cells, i.e., mouse dendritic DC2.4 
cells, mouse splenic macrophages, mouse BMDCs, and human PBMCs, respond to CpG 
polypodna more efficiently than to single-stranded CpG DNA. Similar results of pod 
number-dependent cytokine production were observed in mice. These results strongly suggest 
that assembly of CpG DNA into polypod-like or dendritic structures is a versatile and useful 
method by which to increase the potential of CpG DNA as a vaccine adjuvant without using 
chemically stabilized DNA analogues. 
 The detailed mechanism whereby polypodna preparations induce large amounts of 
cytokines has yet to be fully elucidated, but likely involves the efficient interaction of CpG 
DNA with its receptor, TLR9. One important factor contributing to the interaction is the 
cellular uptake of CpG DNA. We found that the cellular uptake of polypodna increased with 
increasing pod number in RAW264.7 cells
17
 and DC2.4 cells (Figure 2B). We also showed 
that the cellular uptake of hexapodna consisting of 240 nucleotides is higher than that of 
penta-, tetra- or tripodna of the same number of nucleotides.
17
 The significant inhibition of 
IL-6 production following treatment with the inhibitors (Figure 2C) used suggested that 
several mechanisms, including endosomal fusion and acidification, clathrin-mediated 
17 
endocytosis, and phagocytosis, are involved in the uptake of polypodna by the cells. Taken 
together, these results advocate the hypothesis that DNA assemblies with a bulky structure 
have a high potential to interact with cells. This hypothesis is supported by experimental 
evidence that long ODNs are more efficiently taken up by RAW264.7 cells than short ones.
27 
 It has been suggested that the cellular uptake of DNA is not mediated by the 
interaction of TLR9 and CpG DNA.
28
 Consistent with this, we found that the cellular uptake 
of CpG or GpC hexapodna in wild-type or TLR9
-/-
 splenic macrophages was similar (Figure 
3D). Our previous study suggests that polypodna shares the uptake mechanism with single- or 
double-stranded DNA.
17
 Studies using phosphorothioate-stabilized CpG DNA concluded that 
long retention in endosomes explains the high ability of multimeric CpG DNA to produce 
large amounts of IFN- from plasmacytoid dendritic cells (pDCs) compared with monomeric 
CpG DNA.
29, 30
 Although the detailed mechanism governing the cellular uptake of polypodna 
remains to be determined, these results suggest that the structure-dependent increase in uptake 
leads to increased interaction of CpG DNA with TLR9 in endosomes due to its higher 
concentration and possibly longer retention time in these vesicles. 
 An important finding of the present study is that the immunostimulatory activity of 
CpG polypodna is solely dependent on TLR9 ligation. Splenic macrophages and BMDCs of 
TLR9
-/-
 mice released no significant amount of cytokines when treated with CpG polypodna 
preparations (Figure 3C and data not shown). When treated with imoquimod, a ligand for 
TLR7, TLR9
-/-
 splenic macrophages and BMDCs released large amounts of IL-12 and IL-6, 
respectively (data not shown), indicating that the cells have the ability to release cytokines. In 
addition, these results strongly suggest that TLR9, rather than other intracellular DNA sensors 
that recognize DNA irrespective of CpG motifs,
24, 31-33
 is the major polypodna sensor. This 
was also supported by the almost complete inhibition of CpG hexapodna-induced IL-6 release 




 Our previous in vivo study indicated that tetrapodna preparations are more effective 
in inducing IL-12p40 than ssDNA. The present study further confirmed this finding and 
clearly demonstrated that cytokine production is dependent on the pod number, as observed in 
experiments using cultured cells. These results provide experimental evidence that polypodna 
preparations with many pods are useful for in vivo applications compared with ones with 
fewer pods.       
 Human PBMCs consist of several types of cells, including TLR9-positive pDCs. It 
has been reported that pDCs release IFN- upon recognition of CpG DNA by TLR9 .8, 35 
IFN- activates many types of immune cells, including natural killer cells,36 DCs,37 T cells,38 
and B cells,
39
 so that the induction of IFN- release would be useful for the initiation of an 
immune response. We found that polypodna induced significantly greater amounts of IFN- 
secretion from human PBMCs than ssDNA (Figure 6B), although the pod number-dependent 
increase in human cells was less clear than in the murine counterparts. This might be 
explained by differences in experimental conditions, including the type of cells and cytokines 
measured. The PBMCs used would contain only 0.2-0.8% pDC and many more monocytes 
and T cells, according to the literature.
35, 40
 With the exception of pDCs, human monocytes 
very weakly express TLR9.
41, 42
 Therefore, cells other than pDCs, such as monocytes, might 
be involved in IFN- release from human PBMCs. 
 The current standard therapy for HCV is a combination of pegylated IFN- and 
ribavirin.
43
 Our preliminary study using the HCV subgenomic replicon system demonstrated 
that IFN- treatment reduced the luciferase activity of the cells, but relatively high IFN- 
concentrations (10 IU/mL, corresponding to about 2500 pg/mL, or greater) were required for 
significant reduction in activity. Because the conditioned medium of human PBMCs 
containing about 50 pg/mL (20-fold diluted) inhibited the luciferase activity to less than 10% 
19 
(Figure 6C), this clearly suggests that cytokines other than IFN- are released from human 
PBMCs by addition of CpG hexapodna. Thus, hexapodna or other highly branched DNA 
assemblies, including dendrimer-like DNA, containing immunostimulatory sequences, such as 
CpG motifs, can be effective in inhibiting HCV replication. 
 In conclusion, we have demonstrated that building CpG DNA into polypod-like 
structures is a versatile and useful method by which to increase its uptake and cytokine 
production in many immune cell types, including human PBMCs, and in mice. Based on these 
findings, we propose that polypodna preparations are natural, biodegradable and highly potent 




Figure 1. Sequence and planar representation of CpG polypodna for mouse cells. (A) CpG 
tripodna, (B) CpG tetrapodna, (C) CpG pentapodna, and (D) CpG hexapodna. Each ODN was 
identified with different colors. 
 
Figure 2. IL-6 release and uptake of ssDNA or polypodna after addition to mouse dendritic 
DC2.4 cells. (A) DC2.4 cells were treated with ssDNA or polypodna at a final concentration 
of 1, 2 or 4 g/mL and incubated at 37C for 24 h. The concentrations of IL-6 in culture 
media were measured by ELISA. Results are expressed as mean  SD of four wells. Data are 
representative of three independent experiments. *P<0.05 compared with the ssDNA-treated 
group. (B) DC2.4 cells were treated with Alexa Fluor 488-labelled ssDNA or polypodna at a 
final concentration of 2 g/mL and incubated at 37C for 8 h. The amounts of DNA 
associated with the cells were measured by flow cytometry, and the normalized MFI was 
calculated to compare the cellular uptake of DNA samples. Results are expressed as mean  
SD of six wells. Data are representative of three independent experiments. *P<0.05 compared 
with the ssDNA-treated group. (C) DC2.4 cells were incubated with none, 6.25 μM 
chloroquine (CQ), 25 μM monodansylcadaverine (MDC), or 5 μM cytochalasin B (CyB) for 
30 min, then treated with hexapodna (2 g/mL) or LPS (25 ng/mL) and incubated at 37C for 
24 h. The concentrations of IL-6 in culture media were measured by ELISA. Results are 
expressed as mean  SD of four wells. Data are representative of two independent 
experiments. *P<0.05 compared with the untreated (control) groups. (D) DC2.4 cells were 
incubated with none, 6.25 μM chloroquine (CQ), 25 μM monodansylcadaverine (MDC), or 5 
μM cytochalasin B (CyB) for 30 min, then treated with hexapodna (2 g/mL) and incubated 
at 37C for 8 h. The amounts of DNA associated with the cells were measured by flow 
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cytometry. Results are expressed as the % of control (the none group; MFI, 176.2)  SD of 
four wells. Data are representative of two independent experiments. *P<0.05 compared with 
the none (control) group. 
Figure 3. IL-12p40 release and uptake of ssDNA or polypodna after addition to mouse 
splenic macrophages. (A-C) Splenic macrophages from (A, B) wild-type C57/BL6 mice or 
(C) TLR9
-/-
 mice were treated with ssDNA or polypodna containing (A, C) CpG or (B) GpC
motifs at a final concentration of (A) 1, 2 or 4 g/mL or (B, C) 2 g/mL and incubated at 
37C for 24 h. The concentrations of IL-12p40 in culture media were measured by ELISA. 
Results are expressed as mean  SD of four wells. Data are representative of three 
independent experiments. *P<0.05 compared with (A) the ssDNA-treated group or (B, C) the 
medium-treated group. (D) Splenic macrophages from wild-type or TLR9
-/-
 mice were treated
by Alexa Fluor 488-labelled hexapodna containing CpG or GpC motifs at a final 
concentration of 2 g/mL and incubated at 37C for 4 h. The amounts of DNA associated with 
cells were measured by flow cytometry. Results are expressed as mean  SD of three wells. 
Data are representative of two independent experiments. 
Figure 4. IL-6 release after addition of ssDNA or polypodna to mouse BMDCs. BMDCs were 
treated with ssDNA or polypodna at a final concentration of 2 g/mL and incubated at 37C 
for 24 h. The concentrations of IL-6 in culture media were measured by ELISA. Results are 
expressed as mean  SD of three wells. Data are representative of three independent 
experiments. *P<0.05 compared with the ssDNA-treated group. 
Figure 5. Serum IL-12p40 concentration after intradermal injection of ssDNA or polypodna 
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into mice. Mice received an injection of ssDNA or polypodna at a dose of 100 g/mouse, and 
blood was collected from the tail vein at indicated periods of time after injection. The 
concentrations of IL-12p40 in serum were measured by ELISA. Results are expressed as 
mean  SD of six mice. Data are representative of two independent experiments. *P<0.05 
compared with the ssDNA-treated group. 
Figure 6. IFN- release from human PBMCs and inhibition of HCV replication in LucNeo#2 
cells after addition of ssDNA or polypodna to human PBMCs. (A) PAGE analysis of 
polypodna preparations containing human CpG motifs. Each sample was run on a 6 % 
polyacrylamide gel at 200 V for 20 min. Lane 1, 100-bp DNA ladder; lane 2, ssDNA; lane 3, 
tripodna; lane 4, tetrapodna; lane 5, pentapodna; lane 6, hexapodna. (B) PBMCs were treated 
with ssDNA or polypodna at a final concentration of 2 g/mL and incubated at 37C for 24 h. 
The concentrations of IFN- in culture media were measured by ELISA. Results are 
expressed as mean  SD of five wells. Data are representative of four independent 
experiments. *P<0.05 compared with the ssDNA-treated group. (C) PBMCs were incubated 
with ssDNA or polypodna as described above. Then, the conditioned medium was diluted 
20-fold, added to LucNeo#2 cells, and the cells were incubated at 37C for 24 h. Finally, the 
luciferase activity of the cell lysates was measured as an indicator of HCV replication. Results 
are expressed as mean  SD of five wells. Data are representative of three independent 
experiments. *P<0.05 compared with the ssDNA-treated group. 
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Table 1. The sequences of ODNs used for polypodna preparations for mouse cells. 
ODN Sequence (5′→3′) 
mTri-1 TCGTCAACGTCTGTGCTCTCACGTTGACGCTGTCGA 
mTri-2, mTet-2, mPen-2, mHex-2 TCGACAGCGTCAACGTGAAACGTGAAGCGTCTGCGA 
mTri-3, mPen-3, mHex-3 TCGCAGACGCTTCACGTTGAGCACAGACGTTGACGA 
mTet-1, mPen-1, mHex-1 TCGCTGACGTTGCAGACATCACGTTGACGCTGTCGA 
mTet-3 TCGCAGACGCTTCACGTTGCAGACAGACGTTGACGA 
mTet-4 TCGTCAACGTCTGTCTGCTGTCTGCAACGTCAGCGA 




mGCTri-1 TGCTCAAGCTCTGTGCTC TCAGCTTGAGCCTGTGCA 
mGCTri-2, mGCTet-2, mGCPen-2, 
mGCHex-2 
TGCACAGGCTCAAGCTGA AAGCTGAAGGCTCTGGCA 
mGCTri-3, mGCPen-3, mGCHex-3 TGCCAGAGCCTTCAGCTT GAGCACAGAGCTTGAGCA 
mGCTet-1, mGCPen-1, mGCHex-1 TGCCTGAGCTTGCAGACA TCAGCTTGAGCCTGTGCA 
mGCTet-3 TGCCAGAGCCTTCAGCTT GCAGACAGAGCTTGAGCA 
mGCTet-4 TGCTCAAGCTCTGTCTGC TGTCTGCAAGCTCAGGCA 
mGCPen-4, mGCHex-4 TGCTCAAGCTCTGTGCTC GCAGGCTCTTAAGCTGCA 
mGCPen-5 TGCAGCTTAAGAGCCTGC TGTCTGCAAGCTCAGGCA 
mGCHex-5 TGCAGCTTAAGAGCCTGC AGAGCTTCAGGACTAGCA 
mGCHex-6 TGCTAGTCCTGAAGCTCT TGTCTGCAAGCTCAGGCA 
mGCHex-6 TGCTAGTCCTGAAGCTCT TGTCTGCAAGCTCAGGCA 
All ODNs have a phosphodiester backbone. 
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Table 2. The sequences of ODNs used for polypodna preparations for human cells. 
ODN Sequence(5′→3′) 
hTri-1, hTet-1, hPen-1, hHex-1 TCGTCGTTCCGTCGTTACACTGCTCTGGCGGTCGTT 
hTri-2, hTet-2, hPen-2, hHex-2 AACGACCGCCAGAGCAGTCGTGTCGTACTACGACGA 
hTri-3 TCGTCGTAGTACGACACGGTAACGACGGAACGACGA 
hTet-3, hPen-3, hHex-3 TCGTCGTAGTACGACACGGTCGTAAGCCTGGTCGTA 
hTet-4 TACGACCAGGCTTACGACGTAACGACGGAACGACGA 




hGCTri-1, hGCTet-1, hGCPen-1, 
hGCHex-1 
TGCTGCTTGCCTGCTTACACTGCTCTGGCGGTGCTT 




hGCTet-3, hGCPen-3, hGCHex-3 TGCTGCTAGTAGCACAGCGTGCTAAGCCTGGTGCTA 
hGCTet-4 TAGCACCAGGCTTAGCACGTAAGCAGGCAAGCAGCA 
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